Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Three leading European Comprehensive Cancer Centres launch an international cooperation at top level

27.08.2008
Three European cancer centres in Paris (Institut Gustave Roussy), Amsterdam (Netherlands Cancer Institute) and in Stockholm (Karolinska Institutet), have joined forces in their battle against cancer.

In a collaborative effort, the European Comprehensive Cancer Centre Alliance (ECCCA) strives to develop and implement innovative strategies to improve cancer cure and reduce treatment related side effects.

With a strong focus on combining rationally designed targeted agents with radiotherapy, ECCCA brings together powerful technological platforms of genomics, proteomics and preclinical evaluation tools to identify promising agents for combined application in early clinical trials.

On September 5th this cooperation will start with an inauguration symposium, organised at the NKI, where ECCCA will present its strategic plan, technical platforms and will announce the first three clinical translational trials that will be activated in the three participating centres.

Innovative trials

The cooperation will start immediately with a number of innovative trials. Each institute has submitted a trial that will be executed in all three institutes. In the trials, findings from the lab are “directly” brought into the clinic for evaluating their clinical efficacy. The combined knowledge and facilities in the field of fundamental, translational and clinical research means that it is possible to make rapid progress in this respect. All three trials are characterized by the combination of innovative radiation techniques with translational research.

Image guided Radiotherapy

The trial of the NKI-AVL is aimed at a new concept in breast-conserving treatment. During this treatment only the tumour, rather than the whole breast, is irradiated. A short irradiation schedule will be applied, while using image-guided techniques with a CT scan on the linear accelerator (Image Guided Accelerated Partial Breast Irradiation). The tumour response to treatment will be measured with PET and MRI spectrometry. Simultaneously, genetic analysis is done on the tumour tissue, whereby the response to the treatment is scored. It is anticipated that by looking at the response, it can be predicted which patients are suitable for this limited short treatment. The genetic changes during the radiation will also indicate which drugs may enhance the cell-killing effect of radiation.

Stereotactic Body radiotherapy (SBRT) in advanced lung cancer as an adjunctive to pharmaceutical treatment

With SBRT, tumours can be irradiated with high precision, sparing damage to surrounding healthy tissue. This technology was pioneered at Karolinska and is now being tested for various tumour indications. In this study, initiated by Karolinska, SBRT will be given to both primary tumours and metastatic locations, followed by conventional chemotherapy. The goal is to control tumours in locations that can be identified by novel imaging techniques (PET/CT). After SBRT the tumour disease will return to a less advanced stage, for which chemotherapy will be more effective. The goal of the treatment is to substantially prolong the patient’s survival and also to counteract tumour related symptoms.

Inhibition of the PI3-kinase/AKT/mTOR axis during Radiotherapy

Of the molecular anomalies identified in non-small cell lung cancer, EGFr mutation or overexpression, mutations of the RAS oncogene or the PTEN tumour suppressor gene are among the most frequently observed. All of these alterations signal through the PI3-kinase/AKT/mTOR pathway, which is critical for tumour escape from radiation induced cell death.

This trial initiated by IGR, aims at combining radiotherapy for locally advanced non small cell cancer (non metastatic,) sequential radio-chemotherapy and everolimus, an inhibitor of mTOR (RAD001). The first objective is to assess the safety of the combination. In parallel, prospective functional and metabolic imaging will be used (angio scanner and PET) to monitor tumour response. Tumour tissue will also be prospectively collected to define molecular patterns of responding tumours.

Ramona Pauwels | alfa
Further information:
http://www.nki.nl

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>